The NAMDC Fellowship Program will offer a unique training opportunity to senior postdoctoral clinical fellows who we anticipate will move on to the attending/assistant professor level in an academic setting as well-trained clinician scientists. The focus is on translational medicine, teaching of diagnostic expertise and the development of clinical trials expertise.
We aim to train the first of a new generation of clinician scientists who will be well equipped to move the promising new treatments for mitochondrial disease into the clinical arena. Seven training sites are collaborating in this program. These sites;Columbia, San Diego, Seattle, Cleveland, Hamilton, CHOP and the University of Florida are all leading institutions in the new field of mitochondrial medicine. Each site brings a novel set of training experiences. World renowned faculty are to be found at each site. The initial exposure to mitochondrial patients, diagnosis and treatment will be provided during 6 months at UCSD in the Mitochondrial and Metabolic Disease Center. In this 6 month period an intensive clinical trials training program will be required through the CREST program. Fellows will then choose two 3 month visits to two consortium sites where a rich and varied training experience will be provided. The program will be held together by regular telemedicine conferences involving all consortium sites. At the end of their training the fellows will be encouraged to write a K award application.
|Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66|
|Shen, Lishuang; Diroma, Maria Angela; Gonzalez, Michael et al. (2016) MSeqDR: A Centralized Knowledge Repository and Bioinformatics Web Resource to Facilitate Genomic Investigations in Mitochondrial Disease. Hum Mutat 37:540-8|
|Engelstad, Kristin; Sklerov, Miriam; Kriger, Joshua et al. (2016) Attitudes toward prevention of mtDNA-related diseases through oocyte mitochondrial replacement therapy. Hum Reprod 31:1058-65|
|Karaa, Amel; Kriger, Joshua; Grier, Johnston et al. (2016) Mitochondrial disease patients' perception of dietary supplements' use. Mol Genet Metab 119:100-8|
|Marin, Samantha E; Saneto, Russell P (2016) Neuropsychiatric Features in Primary Mitochondrial Disease. Neurol Clin 34:247-94|
|Al-Mehmadi, Sameer; Splitt, Miranda; For DDD Study group* et al. (2016) FHF1 (FGF12) epileptic encephalopathy. Neurol Genet 2:e115|
|Huang, Xiaoping; Bedoyan, Jirair K; Demirbas, Didem et al. (2016) Succinyl-CoA synthetase (SUCLA2) deficiency in two siblings with impaired activity of other mitochondrial oxidative enzymes in skeletal muscle without mitochondrial DNA depletion. Mol Genet Metab :|
|Saneto, Russell P (2016) Alpers-Huttenlocher syndrome: the role of a multidisciplinary health care team. J Multidiscip Healthc 9:323-33|
|Torres-Torronteras, Javier; Cabrera-PÃ©rez, Raquel; Barba, Ignasi et al. (2016) Long-Term Restoration of Thymidine Phosphorylase Function and Nucleoside Homeostasis Using Hematopoietic Gene Therapy in a Murine Model of Mitochondrial Neurogastrointestinal Encephalomyopathy. Hum Gene Ther 27:656-67|
|ServiÃ¡n-Morilla, Emilia; Takeuchi, Hideyuki; Lee, Tom V et al. (2016) A POGLUT1 mutation causes a muscular dystrophy with reduced Notch signaling and satellite cell loss. EMBO Mol Med 8:1289-1309|
Showing the most recent 10 out of 38 publications